Bookmark

Add to MyYahoo RSS

Synageva BioPharma News

News on Synageva BioPharma (Ticker: TRMS) continually updated from thousands of sources around the net.

Monday Jul 21 | AmericanBankingNews.com

Synageva BioPharma Corp Given Consensus Rating of "Buy" by Analysts

Synageva BioPharma Corp has been given an average recommendation of "Buy" by the ten ratings firms that are currently covering the stock, AnalystRatingsNetwork.com reports .

Comment?

Related Topix: Biotech, Medicine, Trimeris, Healthcare Industry

Thu Jul 10, 2014

Freshnews

GlycoMimetics Appoints Mark A. Goldberg, M.D. to Board of Directors

GAITHERSBURG, Md. -- -- GlycoMimetics, Inc. announced today the addition of Mark A. Goldberg, M.D. to its Board of Directors.

Comment?

Related Topix: Gaithersburg, MD, Medicine, Brigham and Women's Hospital, Hospital Administration, Healthcare Industry, DanaFarber Cancer Institute, Oncology, Hematology

Wed Jul 02, 2014

Hispanic Business

Synageva Biopharma Corp. Files SEC Form 4, Statement of Changes in...

There was one document filed with this form. The 02421, 357-9900. Our editors provided additional information about Form 4: Every director, officer or owner of more than ten percent of a class of equity securities registered under Section 12 of the '34 Act must file with the Commission a statement of ownership regarding such security.

Comment?

Related Topix: Biotech, Trimeris, Medicine, Healthcare Industry

Tue Jul 01, 2014

AmericanBankingNews.com

JPMorgan Chase & Co. Reiterates "Overweight" Rating for Synageva BioPharma Corp

's stock had its "overweight" rating reaffirmed by analysts at JPMorgan Chase & Co.

Comment?

Related Topix: Biotech, Medicine, Trimeris, Healthcare Industry, Banking, JP Morgan Chase

Mon Jun 30, 2014

Applied Clinical Trials

Synageva BioPharma? Reports Positive Top-Line Results From Phase 3...

Phase 3 Study Meets Primary Endpoint and Six Secondary Endpoints Across Multiple Disease-Related Abnormalities Conference Call and Webcast to be Held Today at 4:30 p.m. EDT /PRNewswire/ -- Synageva BioPharma Corp. , a biopharmaceutical company developing therapeutic products for rare diseases, announced today that the global, randomized, ... (more)

Comment?

Related Topix: Biotech, Trimeris, Medicine, Healthcare Industry

Freshnews

Synageva BioPharma(TM) Reports Positive Top-Line Results From Phase 3 ...

Synageva BioPharma Corp. , a biopharmaceutical company developing therapeutic products for rare diseases, announced today that the global, randomized, double-blind, placebo-controlled Phase 3 ARISE trial of sebelipase alfa in 66 children and adults with lysosomal acid lipase deficiency met the primary endpoint of normalization of alanine ... (more)

Comment?

Related Topix: Biotech, Trimeris, Medicine, Healthcare Industry

•••
•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••